Compare Charles River Laboratories Intl. Inc (CRL) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Skyworks Solutions Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Skyworks Solutions Inc trades at $57.55 (market cap $8.51B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 5.02% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SWKS | |
|---|---|---|
Market Cap | $11.14B | $8.51B |
Sector | Health | Technology |
52-Week High | $233.60 | $83.40 |
52-Week Low | $145.57 | $52.50 |
Enterprise Value | $14.00B | $8.28B |
Dividend Yield | — | 5.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Skyworks Solutions (SWKS) trades at $58.24, down 3.51% amid bearish technical signals, though recent earnings beats and a 60% analyst buy rating suggest underlying strength. The company maintains solid fundamentals with $4.09B revenue and 8.93% net margin, while expanding into AI and EV markets through recent product launches. Cash flow trends show variability, with 2025 net cash flow negative at -$207M after positive flows in prior years.
The stock presents a value opportunity with consensus price target of $72.56 offering 25% upside, supported by dividend yield above 4% and strategic positioning in growing semiconductor segments. Key risks include ongoing legal investigations and customer concentration, but strong analyst support and technical oversold conditions near support at $55 indicate potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
